Prognostic Value ofBRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer

Colon Cancer, Version 3.2014

(2017) Al B. Benson et al.   Journal of the National Comprehensive Cancer Network

Prognostic Effect ofBRAFandKRASMutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab

(2016) Julien Taieb et al.   JAMA Oncology

Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)

(2015) F. A. Sinicrope et al.   CLINICAL CANCER RESEARCH

Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes

(2015) Frank A. Sinicrope et al.   GASTROENTEROLOGY

Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers

(2015) E.M.V. de Cuba et al.   INTERNATIONAL JOURNAL OF CANCER

Clinical and prognostic value of MET gene copy number gain and chromosome 7 polysomy in primary colorectal cancer patients

(2015) An Na Seo et al.   TUMOR BIOLOGY

HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment

(2015) S. M. Kavuri et al.   Cancer Discovery

Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2014) E. Van Cutsem et al.   ANNALS OF ONCOLOGY

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset

(2014) H. Blons et al.   ANNALS OF ONCOLOGY

KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF-Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)

(2014) H. H. Yoon et al.   CLINICAL CANCER RESEARCH

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial

(2014) Julien Taieb et al.   LANCET ONCOLOGY

Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

(2014) Fotios Loupakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predictive and Prognostic Analysis of PIK3CA Mutation in Stage III Colon Cancer Intergroup Trial

(2013) Shuji Ogino et al.   JNCI-Journal of the National Cancer Institute

Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions

(2013) Felipe De Sousa E Melo et al.   NATURE MEDICINE

Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?

(2012) Tomoya Yokota   Anti-Cancer Agents in Medicinal Chemistry

Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers

(2012) Y. Imamura et al.   CLINICAL CANCER RESEARCH

Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value

(2012) P. G. Gavin et al.   CLINICAL CANCER RESEARCH

Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer

(2012) Daniel J. Sargent   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma

(2012) Frank Benedix et al.   PATHOLOGY RESEARCH AND PRACTICE

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

(2011) C. Bokemeyer et al.   ANNALS OF ONCOLOGY

Prognostic Significance and Molecular Associations of Tumor Growth Pattern in Colorectal Cancer

(2011) Teppei Morikawa et al.   ANNALS OF SURGICAL ONCOLOGY

Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803

(2011) S. Ogino et al.   CLINICAL CANCER RESEARCH

p53 mutation is common in microsatellite stable, BRAF mutant colorectal cancers

(2011) Catherine E. Bond et al.   INTERNATIONAL JOURNAL OF CANCER

Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer

(2011) Gordon Hutchins et al.   JOURNAL OF CLINICAL ONCOLOGY

The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients

(2010) A. Fariña-Sarasqueta et al.   ANNALS OF ONCOLOGY

Role of the Serrated Pathway in Colorectal Cancer Pathogenesis

(2010) Barbara Leggett et al.   GASTROENTEROLOGY

Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial

(2009) Arnaud D. Roth et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Distinct CpG island methylation profiles andBRAFmutation status in serrated and adenomatous colorectal polyps

(2008) Yong Ho Kim et al.   INTERNATIONAL JOURNAL OF CANCER

KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

(2008) Astrid Lièvre et al.   JOURNAL OF CLINICAL ONCOLOGY